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Abstract
Background: Cervical cancer is increasing at 1.5% per year in Ireland with 50% mortality giving
2.2% of all cancer deaths. In the Mid-West region a pilot screening programme has begun to screen
all women 25–60 years. 66% of Genitourinary/Sexually transmitted disease (GU/STD) clinics'
abnormal smears are <25 years. Requests to abandon "opportunistic" screening prompted this GU/
STD clinic audit.
Methods: 221(8.4%) patients referred to colposcopy over 4 years were audited. Retrospective
analysis was carried out on GU/STD clinic files, hospital files and computer records for biopsy
reports. Ethical approval was prospectively granted.
Results: 2637 smears were carried out from November 1999 – September 2003.
221 patients referred to colposcopy were audited.
1%, 3%, 5% had severe, moderate and, mild dyskaryosis, respectively, on cervical screening while
0.8%, 1.2%, 1.5% had CIN3, CIN2, CIN1 abnormalities, respectively, on biopsy with 3.5% having no
abnormality (Cervical Intraepithelial Neoplasia = CIN).
53% referred to colposcopy were <25 years.
Conclusion: 2% had high grade lesions. 37% of high grade lesions are <25 years.
Of the high grade lesions 13% had Chlamydia trachomatis (27% of CIN3) and 44% had HPV despite
Relative Risks (RR) being 0.75 and 1.09 respectively. Older women had higher grade changes.
No statistical difference was found for progression, regression and persistence in those over and 
under 25.
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Introduction
Cervical cancer is the second most common cancer in
women worldwide and accounts for 273,000 deaths (9%
of female cancers) annually and 2.7 million of women life
years lost worldwide [1], but only 0.3 million of these are
in developed countries. However, the incidence has been
greatly reduced in countries where routine Papanicolaou
(Pap) testing is accessible. Cervical cancer is increasing at
1.5% per year [2] in Ireland, rising by 36% from
1994–2000, with 50% mortality accounting for 2.2% of
all cancer deaths in women [3]. There is lifetime risk of 1
in 25 of developing this cancer, unscreened, by the age of
75. Currently 77 women die in Ireland each year from cer-
vical cancer [4]. Thus it poses an important Public Health
problem. The National Cervical Screening Programme
(NHSCSP) has reduced mortality in England and Wales
[3]. Phase 1 of the Irish Cervical Screening Programme
(ICSP) in the Mid-Western Health Board looks promising
and is providing a solid foundation for national roll out.
Cytological analysis of cervical smears satisfies most of the
Wilson and Junger principles for a screening programme
as cervical cancer is prevalent in the community; its natu-
ral history is reasonably well understood, with a believed
long latency period from HPV infection to invasive dis-
ease. Treatment at an early stage is advantageous for the
patient and the community, and adequate facilities are
available for the diagnosis and treatment of abnormalities
identified. However, the Pap cervical smear is not without
its problems with sensitivity of ~55% but regular screen-
ing may account for the success of the programmes. Prob-
lems with this programme have been noted; high risk
women have not attended, false negative results
(18.5–48%) have been noted. A high grade abnormality
does not automatically mean a high grade lesion or visa
versa.
A Department of Health Cervical Screening Committee in
Ireland reported in 1996 that it is worthwhile to screen
25–60 year olds, 10 years longer than is recommended by
World Health Organisation (WHO) and International
Agency for Cancer Research (IACR).
The basis for this recommendation is that despite the high
rate of abnormal smear results in women under 25 years,
invasive cervical cancer is rare in this age bracket [5,6].
Some have argued that over diagnosis, over-treatment and
anxiety generated by screening the under 25 age group
yields little diagnostic benefits [4]. However, high grade
dyskaryosis has increased particularly in <25 year olds
(1.3%–1.9%). This accounts for a rise from 15% to 23%
of all the high grade lesions [7]. In this GU/STD clinic
there is a known 25% abnormality rate in Pap smear
(10% ≥ mild dyskaryosis) in the last 18 years where the
mean patient age is 23 years. This is similar to a Dublin
GU/STD clinic (22%) [8]. It is reported that GUM patients
have a higher rate of cytological abnormalities [9]. A
request to abandon "opportunistic" screening in the Mid
West region outside of the Irish Cervical Screening Pro-
gramme (ICSP) prompted this audit.
Methods
All cervical smear results from November 1999 to Septem-
ber 2003 were audited in the GU/STD Clinic, Mid Western
Regional Hospital, Limerick. All Pap smears were taken by
Ayers spatula and Cytobrush [10,11]. All patients who
had a smear with moderate or severe dyskaryosis or had 2
smears with mild dyskaryosis were referred to colposcopy.
These patients were identified and their GU/STD and hos-
pital files (hard copy) were audited. Where there was no
hospital file or biopsy/lesion report available the histol-
ogy computer data base was accessed to find biopsy and
lesion analysis reports. All demographic details of patients
were entered in an Excel spreadsheet, noting age, smear
report, referral date, colposcopy impression and biopsy
and loop excision reports as well as whether patients had
clinically obvious HPV infection or tested positive for
Chlamydia trachomatis(Ct) (LCx Abbott test). Correlation
of Pap smear and biopsies was undertaken.
Relative risks (RR) and 95% confidence intervals (CI) dif-
ferences were calculated using Excel spreadsheets. Those
aged <25 years were compared to the entire group. Histol-
ogy was taken as the "gold standard". Ethical approval was
granted by the Drug and Therapeutic Ethical Committee
of the Mid Western Regional Hospital, Limerick, Ireland.
Results (summarised in table 1)
2637 smear results were audited. 7% were deemed "unsat-
isfactory" for reporting. 221(8%) were referred to Colpos-
copy. All GU/STD clinic files (221) and 140 hospital files
were available for audit. A computer search for reports
revealed another 9 reports.
Table 2 shows the varying degrees of dyskaryosis and the
histological findings of patients' cervical biopsies and
loop excisions taken at colposcopy. Those under 25 years
are noted separately.
High grade lesions were found in 22%, 42%, 64% of mild,
moderate and
severe dyskaryosis while in <25 year olds it was 14%, 36%
& 57%.
Biopsy results were accrued and compared for Human Pap-
illoma
Virus (HPV) and Chlamydia trachomatis (CT).BMC Research Notes 2008, 1:24 http://www.biomedcentral.com/1756-0500/1/24
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These results are seen in Table 3.
The RR of patients who attended the clinic with HPV and
Ct were evaluated for referral to colposcopy and having a
high grade lesion with these infections.
The results are as follows:
RR of high grade lesion (moderate and severe dyskaryosis)
at smear with (1) HPV = 1.09 and (2) Ct = 0.75. RR of
referral to colposcopy from clinic with (3) HPV = 1.22, (4)
Ct = 0.22. However, if referred to colposcopy RR of high
grade lesion with (5) HPV = 0.88 and (6) Ct = 1.7.
In Table 4 the number of cervical smears that were seen at
colposcopy were analysed to see how many progressed,
regressed or persisted from Pap smear time.
All smears were analysed together and those over and the
under 25 years were separated and 95% CI of the differ-
ences between those over and under 25 were calculated.
No difference was seen between the <25 and >25 year olds
as both age groups progress, regress and persist at similar
rates.
Discussion
221(8.4%) patients screened were referred to colposcopy
of whom 117 (53%) were less than 25 years of age similar
to another Irish GU/STD clinic (56%) [8]. 1%, 3%, 5%
had severe, moderate and, mild dyskaryosis, respectively,
on cervical screening while 0.8%, 1.2%, 1.5% had CIN3,
CIN2, CIN1 abnormalities, respectively, on biopsy with
3.5% showing no abnormality.
High grade lesions were found in 25% of mild, 41% of
moderate and 61% of severe dyskaryosis. The literature
Table 1: Summary of study findings.
Smear 
referral
% of all
(n = 2637)
Biopsy % of all
(n = 2637)
Biopsy 
&<25
Biopsy % 
<25
HPV <25 yrs % HPV Ct <25 yrs % Ct
Severe dyskaryosis/CIN3* 29 1% 22 0.8% 7 32% 11 3 50% 6 5 27%
Moderate dyskaryosis/CIN2* 69 3% 32 1.2% 13 41% 13 8 41% 1 0 3%
Mild dyskaryosis/CIN1* 123 5% 39 1.5% 24 62% 29 17 74% 1 1 3%
NAD 0 0 56 3.5% 39 70% 27 23 48% 4 4 7%
not available 0 0 72 2.0% 34 47% 30 24 88% 16 11 22%
Total 221 8.4% 149 117 53% 80 50 54% 17 14 12%
*Dyskaryosis referred to cytology results and CIN to biopsy results.
CIN = Cervical Intraepithelial Neoplasia. NAD = No active disease.
HPV = Human Papilloma Virus. Ct = Chlamydia trachomatis.
Table 2: Smear and colposcopic findings.
Pap smear results Smear referral % total
(n = 2637)
<25 years % total <25 years % <25 yrs Biopsy result No. <25
yrs
% <25 yrs
Severe Dysplasia 29 1% 9 0.31% 31% CIN3 10 3 30%
CIN2 6 1 17%
CIN1 4 2 50%
NAD 5 1 20%
Not available 4 2 50%
Moderate Dysplasia 69 3% 28 1.2% 41% CIN3 9 3 33%
CIN2 14 6 43%
CIN1 16 7 44%
NAD 16 9 56%
Not available 14 3 21%
Mild Dysplasia 123 5% 80 66% 66% CIN3 3 1 33%
CIN2 12 6 50%
CIN1 19 15 79%
NAD 35 29 83%
Not available 54 29 54%
221 8.4% 117 4.4% 53% 221 117
*Dyskaryosis referred to cytology results and CIN to biopsy results.
CIN = Cervical Intraepithelial Neoplasia. NAD = No active disease.BMC Research Notes 2008, 1:24 http://www.biomedcentral.com/1756-0500/1/24
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reports that mild, moderate and severe dyskaryosis will
give high grade lesions histologically (CIN2 and CIN3) in
50%, 50–75%, 80–90%, respectively, while CIN3 will
have 5% invasion rate [11]. Any differences noted may be
as a result of the age group of these patients being older or
their sample selection. This study population has 37% of
all those with high grade lesions (CIN2 +CIN3) <25 years
while only 12% was seen in a US study [12]. Older
patients (>25 yrs) had a higher prevalence of high grade
lesions with 69%, 59%, 34% of CIN3, CIN2, CIN1 being
>25 yrs, respectively.
It is accepted Progression, Regression and Persistence have
been noted in mild dyskaryosis; 16%, 62%, 22%, moder-
ate dyskaryosis; 35%, 50%,15% [13,14], and regression of
46% [15] in severe dyskaryosis while progression from
CIN1 to CIN3 in 26% was seen in a prospective study
[16]. In this study the Progression, Regression and Persist-
ence rates for mild dyskaryosis were; 21%, 51%, 28% and
moderate dyskaryosis; 16%, 58%, 25% and regression of
60% in severe dyskaryosis. The lower grade lesions had
higher persistence and progression while the higher grade
lesions had a marginally lower rate of progression and
persistence. This was not statistically significant.
Human Papilloma Virus (Type 16) has long been associated
with cervical cancer. There is a 12% risk of recurrent
abnormalities in women with low-risk HPV (non 16 or 18
subtypes) and up to a 50% risk of recurrence in women
with certain types of HPV infection (especially subtypes
16 and 18). A change in the disease process in recent years
is suggested in findings in the UK and Switzerland [17]
where high risk HPV was seen in younger women and may
lead to an increase in cervical cancer. In this study, where
28% of women have HPV infection and it is not feasible
to type the HPV it is reasonable to postulate that at least
3% of all women seen are probably infected with high
grade HPV as it is known that 11% of those with HPV have
high grade HPV in China [18] and 7.2% in teenagers in
the US where 15% had warts and 11% had Chlamydia tra-
chomatis [19].
Transient HPV infection has been postulated for regres-
sion rates found. HPV associated changes have been
reported in literature in 80% of women ≤ 25 years of age,
66% in the age group 26 to 35 years, 51% in the age group
36 to 45 years and 38% in women aged ≥ 46 years (p =
0.03). In this study there has been a high but not as high
a rate of high grade lesions in the >25 year olds (35/54 =
65%) but the rates of progression, regression and persist-
ence are the same in the <25 year olds as was reported by
Wright et al in their study of teenagers with 18% having
high grade lesions [20].
In this study RR of a high grade lesion with clinical HPV
infection was 1.09 but 50% of high grade lesions had
HPV. This RR is in agreement with the advice given to
Table 3: Biopsy reports from patients showing all those with HPV and Chlamydia trachomatis separately. Patients <25 years separated 
in each group.
Biopsy No. HPV+ HPV+ <25 
yrs
% HPV+ <25 
yrs
HPV+ &Ct+ HPV+ &Ct+ 
<25 yrs
% HPV+ &Ct+ 
<25 yrs
Ct+ Ct + <25 yrs % Ct+ <25 
yrs
CIN3 22 10 2 20% 1 1 100% 5 4 80%
CIN2 32 12 7 58% 1 0 0 0 0 0
CIN1 39 29 17 59% 0 0 0 1 1 100%
NAD 56 24 20 83% 3 3 100% 1 1 100%
Not available 72 19 17 90% 11 7 64% 5 4 80%
149 75 46 61% 5 4 80% 12 10 80%
*Dyskaryosis referred to cytology results and CIN to biopsy results.
CIN = Cervical Intraepithelial Neoplasia. NAD = No active disease.
HPV = Human Papilloma Virus. Ct = Chlamydia trachomatis.
Table 4: Progression, Regression and Persistance seen in each dyskaryotic group. Those under and over 25 were separated.
Dyskaryosis All Pap Smears <25 years >25 years 95% CI of difference
progress persist regress progress persist regress progress persist regress progress persist regress
Severe 40% 60% 43% 57% 39% 61% 0.62,-0.70 0.6,-0.52
Moderate 16% 25% 58% 12% 24% 64% 20% 23% 55% 0.56,-0.40 0.14,-0.16 0.25,-0.43
Mild 21% 28% 51% 14% 29% 57% 44% 22% 33% 0.7,-0.121 0.39,-0.53 0.21,-0.69
*Dyskaryosis referred to cytology results and CIN to biopsy results.
CIN = Cervical Intraepithelial Neoplasia.BMC Research Notes 2008, 1:24 http://www.biomedcentral.com/1756-0500/1/24
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women on smear programmes that they do not need to
come more often than the general population.
Other Sexually Transmitted Infections have been impli-
cated in causing dyskaryosis especially Chlamydia trachom-
atis [21]. There is 11% prevalence of Chlamydia trachomatis
in this clinic similar to 9.6% in a Dublin clinic [8]. 27% of
biopsy proven CIN3 had Ct in this study and 80% of those
were <25 years. However, the RR of having a high grade
lesion at time of smear taking with Ct was 0.75 even
though 13% of the study's patients with severe dyskaryo-
sis had Ct.
Early sexual debut has not been audited in many studies
[22,23]. Younger onset of sexual activity [24] is estab-
lished in Ireland and may contribute to the earlier age of
onset of this cancer. In the 20 patients in this study with
high grade lesions sexual debut was available in 8. 5
patients had first sexual intercourse at 14 years or less, one
admitted child sexual abuse. Another was 15 and the
other 2 were 18 and 19 years of age. These women had a
mean number of 5.5 (range 1–20) sexual partners in their
lives.
Recent analyses of cost-effectiveness suggest that the addi-
tion of molecular HPV DNA testing for women aged over
30 years may allow the screening interval to be lengthened
to 3 years for most women but women at high risk for
HPV infection and its associated cellular atypias warrant
closer monitoring and follow-up. These patients would
include organ transplant recipients, women exposed to
diethylstilbestrol (DES) and HIV-infected women
[25].37% of our patients with high grade lesions were <25
years and 43% of these had HPV and 13% Ct. Should
patients at STI clinics be deemed at risk, too, as it was
shown in the UK that they have a 10 fold increase in CIN3
(2.3%) [26] in 20–24 year olds compared to the general
cervical smear population (0.24%) [27]?
Conclusion
Cytology-based screening programs for cervical cancer
have been effective in reducing cancer incidence and pre-
venting premature deaths worldwide. Although the causal
association between infection with certain high-risk types
of HPV and the development of cervical cancer has been
clearly established, testing for the major risk factor is not
part of current screening practice. Screening under 25 year
olds has had much discussion.
2% (n = 54) of all patient screened (n = 2,637) had high
grade lesions in this study of which 37% (n = 20) were
<25 years. 50% of these had HPV while 13% had Chlamy-
dia trachomatis. Of the 12 patients with Chlamydia tracho-
matis 6 had CIN3. 66% (4/6) were under 25 years. 62%
(5/8) of those under 25 with high grade lesions had sexual
debut under 14 years of age.
Whether or not HPV, Chlamydia trachomatis, early sexual
debut or number of sexual partners pre-empts high grade
lesions leading to cancer of the cervix needs further evalu-
ation. As GUM patients have a 10 fold increase in CIN3
[26] (20–24 year olds) than the general population in the
UK a longer follow up period of these patients would help
establish whether STI clinic patients should be included
with organ transplant recipients, women exposed to
diethylstilbestrol (DES) and HIV-infected women who are
advised to have regular re-screening at younger ages.
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